TRIO Chairman & Executive Director since November 5, 2002
Hailing from New Castle, Pennsylvania, Dr. Dennis Slamon is a world-renowned doctor and researcher. He is revered for his work on the drug Herceptin, a gene-based breast cancer therapy that targets a specific genetic alteration, HER2, found in about 25 per cent of breast cancer patients. The discovery of Herceptin was monumental for cancer research and helped one of the most fatal types of breast cancer become one of the most treatable and manageable.
Dr. Slamon graduated with honours from the University of Chicago’s Pritzker School of Medicine in 1975 and earned his PhD in Cell Biology that same year. After completing his internship and residency at the University of Chicago Hospitals and Clinics, he took the position of chief resident doctor in 1978. One year later, he became a fellow in the Division of Hematology/Oncology at the University of California, Los Angeles (UCLA).
A celebrated medical professional, Dr. Slamon has won nearly two dozen national research awards for his scientific achievements. These awards include the prestigious Medal of Honor from the American Cancer Society and the Friends of the National Library of Medicine Distinguished Medical Service Award.
Dr. Slamon currently serves as Director of Clinical Translational Research at UCLA’s Jonsson Comprehensive Cancer Center, and continues to make a difference with his impactful research for treating cancer.